European Companies Search Engine
EU funding (€1,809,140): Linking Ketone Metabolism and Signaling in Heart Failure with Preserved Ejection Fraction Hor9 Dec 2022 EU Research and Innovation programme "Horizon"
Overview
Text
Linking Ketone Metabolism and Signaling in Heart Failure with Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFpEF) is a burgeoning public health problem for which there are little to no evidence-based therapies. This syndrome has proven particularly challenging because of the limited insight into its underlying molecular mechanisms. Metabolic adaptations are critical for cardiomyocyte response to stress. Ketones are metabolites actively produced in heart failure and their role as metabolic rheostat capable of modulating cardiac metabolism and cardiomyocyte signaling pathways has been postulated. However, there is fundamental, open gap in understanding how ketones are utilized as source of energy in HFpEF and how -hydroxybutyrate (-OHB) the most abundant ketone plays a role as non-energy carrier governing cardiomyocyte function. In this project proposal, I hypothesize that ketones are major regulators of cardiomyocyte biology representing an alternative source of fuel in HFpEF (energy role) and act as protein modifiers trough -hydroxybutyrylation a lysine-based post-translational modification (PTM) thereby regulating chromatin architecture, gene transcription and metabolic signaling in cardiomyocytes (non-energy role). The overall aim of KetoCardio is to define mechanisms integrating ketone metabolic adaptation with signaling pathways and epigenetic changes in HFpEF-stressed cardiomyocyte. Coupling proteomics, transcriptomics and genomics approaches together with cardiac and systemic metabolic evaluation and rigorous preclinical experimental modeling of HFpEF, I will be able to define the previously unrecognized role(s) of ketones as energy substrates in HFpEF and as substrate for proteins PTM impacting on cardiomyocyte function. In summary, focusing on metabolic pathways that govern cardiomyocyte abnormalities in preclinical HFpEF, this project will provide a transformative molecular understanding of ketones biology in cardiomyocyte fostering innovation in the field and beyond.
Funded Companies:
| Company name | Funding amount |
| CHARITE - UNIVERSITAETSMEDIZIN BERLIN | €1,809,140 |
Source: https://cordis.europa.eu/project/id/101078307
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: Charité - Universitätsmedizin Berlin, Berlin, Germany.
The visualizations for "CHARITE - UNIVERSITAETSMEDIZIN BERLIN - EU funding (€1,809,140): Linking Ketone Metabolism and Signaling in Heart Failure with Preserved Ejection Fraction"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
